Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Needs More Aggressive Globalization Strategy – Sen. Brown

This article was originally published in The Tan Sheet

Executive Summary

The Ohio Democrat says FDA should be more creative in dealing with globalization problems than asking for funds to put more inspectors in China. Commissioner Hamburg says the agency is aggressive but lacks tools and resources to fully address globalization issues.

You may also be interested in...



FDA Flags Chinese Personal Care Products Maker For Drug GMP Failings

The agency will pursue cosmetics and personal care product companies as pharmaceutical manufacturers if their product labeling strays into drug territory. FDA’s warning letter to Shanghai Huhui Daily Use Chemical Products says its skin protectant cream does not comply with the OTC monograph.

FDA Flags Chinese Personal Care Products Maker For Drug GMP Failings

The agency will pursue cosmetics and personal care product companies as pharmaceutical manufacturers if their product labeling strays into drug territory. FDA’s warning letter to Shanghai Huhui Daily Use Chemical Products says its skin protectant cream does not comply with the OTC monograph.

Sequestration Could Drive An FDA Resources Review

FDA and advocates wait to see how an estimated 7.8% budget cut would be implemented, if enacted. Former agency officials say sequestration could lead to hiring freezes and program delays.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel